Study Synopsis
Protocol title, sponsor, phase, indication, study population, design summary, primary endpoint, and estimated duration in a summary table.
Free Healthcare Template
Study protocol for [trial/procedure] with endpoints and assessments
Use this template to study protocol for [trial/procedure] with endpoints and assessments.
| Field | Details |
|---|---|
| Category | Healthcare |
| Owner | [Team or owner] |
| Version | [Version number] |
| Effective Date | [Date] |
| Review Cycle | [Monthly / Quarterly / Annual / Event-based] |
| Status | [Draft / In Review / Approved] |
Protocol title, sponsor, phase, indication, study population, design summary, primary endpoint, and estimated duration in a summary table.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Disease background, unmet medical need, mechanism of action of the investigational product, and rationale for the study.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Study type (randomized, double-blind, etc.), number of arms, treatment assignment, dosing regimen, visit schedule overview, and study duration.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Inclusion and exclusion criteria as numbered lists. Be specific about age ranges, lab values, and washout periods.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Primary, secondary, and exploratory endpoints with definitions and measurement methods.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Table showing visits vs. procedures/assessments with timing windows.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Sample size calculation, analysis populations, and primary analysis method.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Adverse event definitions, grading scale, reporting timelines, and DSMB oversight. Use Markdown tables for the synopsis, schedule, and eligibility criteria. Include protocol identifiers and version numbers.
| Item | Details | Owner | Status |
|---|---|---|---|
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
| [Item or requirement] | [Describe the relevant detail, evidence, or decision] | [Owner] | [Open / Complete] |
[Add context, assumptions, exceptions, evidence links, screenshots, calculations, or reviewer comments.]
Document review conclusions, approvals, unresolved items, and next review date.
| Role | Name | Date | Notes |
|---|---|---|---|
| Preparer | [Name] | [Date] | [Notes] |
| Reviewer | [Name] | [Date] | [Notes] |
| Approver | [Name] | [Date] | [Notes] |
Template Structure
Use this healthcare template as a starting point, then customize each section to match your internal workflow, evidence, and signoff needs.
Protocol title, sponsor, phase, indication, study population, design summary, primary endpoint, and estimated duration in a summary table.
Disease background, unmet medical need, mechanism of action of the investigational product, and rationale for the study.
Study type (randomized, double-blind, etc.), number of arms, treatment assignment, dosing regimen, visit schedule overview, and study duration.
Inclusion and exclusion criteria as numbered lists. Be specific about age ranges, lab values, and washout periods.
Primary, secondary, and exploratory endpoints with definitions and measurement methods.
Table showing visits vs. procedures/assessments with timing windows.
Sample size calculation, analysis populations, and primary analysis method.
Adverse event definitions, grading scale, reporting timelines, and DSMB oversight. Use Markdown tables for the synopsis, schedule, and eligibility criteria. Include protocol identifiers and version numbers.
Write a Clinical Protocol Document in a formal scientific tone suitable for IRB/Ethics Committee submission. Structure with these sections:
Protocol title, sponsor, phase, indication, study population, design summary, primary endpoint, and estimated duration in a summary table.
Disease background, unmet medical need, mechanism of action of the investigational product, and rationale for the study.
Study type (randomized, double-blind, etc.), number of arms, treatment assignment, dosing regimen, visit schedule overview, and study duration.
Inclusion and exclusion criteria as numbered lists. Be specific about age ranges, lab values, and washout periods.
Primary, secondary, and exploratory endpoints with definitions and measurement methods.
Table showing visits vs. procedures/assessments with timing windows.
Sample size calculation, analysis populations, and primary analysis method.
Adverse event definitions, grading scale, reporting timelines, and DSMB oversight.
Use Markdown tables for the synopsis, schedule, and eligibility criteria. Include protocol identifiers and version numbers.
Protocol ID: CDZ-HTN-2026-001 | Version: 2.0 | Date: 2026-02-01 Sponsor: Valeant Pharmaceuticals | Phase: II | IND Number: 123456
| Item | Detail |
|---|---|
| Title | A Randomized, Double-Blind, Placebo-Controlled Study of Cardizem XR in Stage 1 Hypertension |
| Population | Adults aged 30-70 with Stage 1 hypertension (SBP 130-139 mmHg) |
| Design | 2-arm, parallel group, 1:1 randomization |
| Treatment | Cardizem XR 180 mg QD vs. placebo for 12 weeks |
| Primary Endpoint | Change from baseline in mean 24-hour ambulatory SBP at Week 12 |
| Sample Size | 220 subjects (110 per arm) |
Stage 1 hypertension affects approximately 46% of US adults and is a leading modifiable risk factor for cardiovascular disease. Cardizem XR (diltiazem extended-release) is a calcium channel blocker with established efficacy in moderate-to-severe hypertension. This trial evaluates its benefit-risk profile in the Stage 1 population where lifestyle modification alone is often insufficient.
| Assessment | Screening | Baseline | Week 4 | Week 8 | Week 12 |
|---|---|---|---|---|---|
| Informed consent | X | ||||
| Vital signs | X | X | X | X | X |
| 24-hr ABPM | X | X | |||
| ECG | X | X | |||
| Chemistry panel | X | X | X | ||
| Adverse events | X | X | X | X |
All serious adverse events must be reported to the Sponsor within 24 hours. An independent Data Safety Monitoring Board will conduct interim reviews after 50% enrollment. Adverse events are graded per CTCAE v5.0.
Record a walkthrough, training session, or process demonstration. Docsie AI turns it into structured documentation using this template as the starting framework.
Use the template manually, or let Docsie generate the first draft from source footage.
Data handling for [system/process] with PHI rules and breach reporting
Prevention procedures for [pathogen/setting] with screening and isolation precautions
Testing procedure for [assay/test] with specimen requirements and QC protocols
Operating instructions for [device] with setup, alarms, and troubleshooting
Care procedure for [condition/treatment] with milestones and discharge criteria
Compounding process for [medication] with ingredients, equipment, and QC checks
Template FAQ
Common questions about using and generating a clinical Protocol Document.
Q: What is a clinical Protocol Document?
A: A clinical Protocol Document is a structured document for study protocol for [trial/procedure] with endpoints and assessments.
Q: Can I download this clinical Protocol Document as Word or PDF?
A: Yes. This page includes free downloads in DOCX, PDF, and Markdown formats so you can edit, share, or import the template into your documentation system.
Q: Can Docsie generate this from a video?
A: Yes. Upload a process walkthrough, training recording, or screen capture to Docsie, then use this template structure to generate a first draft automatically.